Type 1A diabetes mellitus and autoimmunity

Česká verzia

Authors: D. Vrlíková; M. Mokáň
Authors place of work: I. interná klinika Jesseniovej lekárskej fakulty UK a Martinskej FN, Martin, Slovenská republika, prednosta prof. MUDr. Marián Mokáň, DrSc.
Published in the journal: Vnitř Lék 2005; 51(11): 1297-1302
Category: Review

Summary

Type 1A diabetes mellitus presents the most frequent part of type 1 DM. This disease is caused by an autoimmune destruction of pancreatic β-cells. Genetic, autoimmune and environmental factors are responsible for the development of type 1 diabetes. The most important genes that determinate te development of the disease are genes of Major Histocompatibility Complex (MHC). There is evidence that viral infection acts as a triggering event of autoimmune reaction. The immune response to a microbial determinant would cross-react with host tissues and results in an activation and proliferation of T-lymphocytes that cause destruction of pancreatic β-cells.

Key words:
type 1A diabetes mellitus - HLA-alels - T-lymphocytes - pancreatic β-cells

Zdroje

1. Acton RT. The major histocompatibility complex. In: Rich RR (ed). Clinical Imunolgy, Principles and Practice. London, Edinburg, New York, Philadelphia, St. Louis, Sydney, Toronto: Mosby 2001: 6.1-6.13.

2. Buc M. Klinická imunológia. Bratislava: Veda 1997.

3. Buc M. Imunológia. Bratislava: Veda 2001.

4. Buc M, Shawkatová I. Imunopatogenéza diabetes mellitus 1A. J Čes Slov pediatria 2002; 57: 299-305.

5. Černá M, Žďárský E, Anděl M. HLA-systém a diabetes mellitus 1. typu. J DMEV 2000; 2: 8-15.

6. Devendra D, Liu E, Eisenbarth GS. Type 1 Diabetes: recent developments. Brit Med J 2004; 328: 750-754.

7. Fourlanos S, Dotta F, Greenbaum CJ et al. Latent autoimmune diabetes in adults (LADA) making it less latent. Autoimmunity 1999; 29: 65-83.

8. Hagopian WA, Sanjevi CB, Kockum I et al. Glutamate decarboxylase, insulin, islet cell autoantibodies and HLA typing to detect diabetes in a general population - based study of Swedish children. J Clin Invest 1995; 95: 1505-1511.

9. Larsen CE, Alper CA. The genetics of HLA-associated disease. J Curr Opin Imunol 2004; 5: 660-667.

10. Leslie D, Valeri C. Latent autoimmune diabetes in adults (LADA). Diabetes Voice 2003; 48: 14-16.

11. Mokáň M. Diabetes mellitus. In: Ďuriš I, Hulín I, Bernadič M (eds). princípy internej medicíny. Bratislava: SAP 2001: 2152-2182.

12. Mokáň M. Diabetes mellitus. In: Šašinka M, Nyulassy Š, Badalík L (eds). Vademecum medici. Martin: Osveta 2003: 959-982.

13. Novák J, Anděl M. Buněčná imunita v patogenezi diabtes mellitus 1. typu. J DMEV 2001; 4: 7-11.

14. Palmer JP, Hirsch IB What´s in a name: Latent autoimmune diabetes of adults, type 1,5, adult-onset, and type 1 diabetes. Diabetes Care 2003; 26: 536-538.

15. Pugliese A. Genetics of type 1 diabetes. Endocrinal Metab Clin North Am, 2004; 33: 1-16.

16. Robles DT, Eisenbath GS. Diabetes and related autoimunne diseases. In: Rich RR (ed). Clinical Imunology, Principles and Practice. London, Edinburg, New York, Philadelphia, St.Louis, Sydney, Toronto: Mosby 2001: 82.1-82.18.

17. Stites DP, Terr AI. Základní a klinická imunologie. Praha: Victoria Publishing 1994.

18. Turský T, Banduchová E. Dekarboxyláza glutamátu - autoantigén pri inzulín-dependentnom diabetes mellitus. J Bratislav Lek Listy 1999; 100: 85-88.

19. Vandewalle ChL, Falorni A, Svanholm S et al. High diagnostic sensitivity glutamate decarboxylase autoantibodies in insulin dependent diabetes mellitus with clinical onset between age 20-40years. J Clin Invest 1996; 98: 2597-2603.

20. Virella G, Goust JM. Organ-specific autoimunne diseases. In: Virella G. (ed). Medical imunology. New York, Basel: Marcel Dekker 2001: 341-376.